SCHEMBL25842178

SCHEMBL25842178

CCCc1c[nH]c2cc(CC=C(C)C)ccc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 6/20 0.42
HTR2C P28335 3/20 0.42
HTR2B P41595 2/20 0.42
HTR1A P08908 6/20 0.40
HTR1D P28221 4/20 0.40
HTR1B P28222 4/20 0.40
MTNR1A P48039 1/20 0.39
MTNR1B P49286 1/20 0.39
CHRNB2 P17787 1/20 0.39
CHRNA7 P36544 1/20 0.39
CHRNA4 P43681 1/20 0.39
NPC1 O15118 1/20 0.39
CYP19A1 P11511 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
SLC6A4 P31645 1/20 0.37
HTR3E A5X5Y0 1/20 0.37
HTR3B O95264 1/20 0.37
HTR1E P28566 1/20 0.37
HTR1F P30939 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16433255 0.89 NPC1 (0.50) HTR2AHTR2CHTR2BHTR1AHTR1D
SCHEMBL25260689 0.88 HTR2A (0.57) HTR2AHTR2CHTR2BHTR1AHTR1D
SCHEMBL29804890 0.88 HTR2A (0.57) HTR2AHTR2CHTR2BHTR1AHTR1D
SCHEMBL25299491 0.87 HTR1D (0.54) HTR2AHTR2CHTR2BHTR1AHTR1D
SCHEMBL25842168 0.86 HTR2A (0.47) HTR2AHTR2CHTR2BHTR1AHTR1D
SCHEMBL25263097 0.85 HTR2A (0.57) HTR2AHTR2CHTR2BHTR1AHTR1D
SCHEMBL25842170 0.82 MTNR1A (0.62) HTR2BHTR1AMTNR1AMTNR1BMEN1
SCHEMBL31549198 0.81 ALDH1A1 (0.48) MTNR1AMTNR1BNPC1MEN1KMT2A
SCHEMBL25842189 0.81 HTR2A (0.54) HTR2AHTR2CHTR2BHTR1AHTR1D
SCHEMBL9373120 0.81 HTR2A (0.47) HTR2AHTR2CHTR2BHTR1AHTR1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230219888-A1 PRENYLATED PSILOCYBIN DERIVATIVES AND METHODS OF USING MAGICMED INDUSTRIES INC. (CA) 2023-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219888-A1 PRENYLATED PSILOCYBIN DERIVATIVES AND METHODS OF USING AANAT, ACAT2, PCYT1A HTR2A 1566/4885HTR2C 1158/4885HTR2B 1023/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.